logo-loader
viewArix Bioscience PLC

Arix Bioscience Plc - Issue of Ordinary Shares and Total Voting Rights

Arix Bioscience Plc - Issue of Ordinary Shares and Total Voting Rights

Arix Bioscience Plc - Issue of Ordinary Shares and Total Voting Rights

PR Newswire

Arix Bioscience plc

Issue of Ordinary Shares and Total Voting Rights

Arix Bioscience plc (the "Company") announces that it has allotted 530,000 new Ordinary Shares to the Arix Bioscience plc Employee Benefit Trust in order to satisfy awards made under the Arix Bioscience plc Executive Incentive Plan.

Application has been made for 530,000 new Ordinary Shares to be admitted to the standard segment of the Official List and to trading on the Main Market of the London Stock Exchange. The new Ordinary Shares will rank pari passu with the existing ordinary shares and it is expected that admission of these new Ordinary Shares will take place at 8.00 a.m. on 2 May 2019.

Following the issue of 530,000 shares the Company will have a total of 135,467,601 ordinary shares of £0.00001 each in issue and a total number of voting rights in the Company of 135,467,601. The above figure of 135,467,601 may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information:

Robert Lyne                        Company Secretary                         +44 (0)207 290 1050

 - Ends -

Quick facts: Arix Bioscience PLC

Price: 111.5

Market: LSE
Market Cap: £151.14 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19